

It is claimed:

1. A pharmaceutical formulation comprising dehydroepiandrosterone (DHEA), at least 85% of which is present as the form I polymorph, and at least one pharmaceutical excipient.

2. The formulation of claim 1, wherein at least 90% of said dehydroepiandrosterone (DHEA) is present as the form I polymorph.

3. The formulation of claim 1, wherein at least 95% of said dehydroepiandrosterone (DHEA) is present as the form I polymorph.

4. The formulation of claim 1, wherein at least 99% of said dehydroepiandrosterone (DHEA) is present as the form I polymorph.

5. A method for preparing a solid DHEA formulation, said method comprising:  
mixing at least one solid pharmaceutical excipient with dehydroepiandrosterone (DHEA), at least 85% of which is present as the form I polymorph.

6. The method of claim 5, wherein at least 90% of said dehydroepiandrosterone (DHEA) is present as the form I polymorph.

7. The method of claim 5, wherein at least 95% of said dehydroepiandrosterone (DHEA) is present as the form I polymorph.

8. The method of claim 5, wherein at least 99% of said dehydroepiandrosterone (DHEA) is present as the form I polymorph.

9. The method of claim 5, further comprising the step of placing the solid formulation into a capsular container suitable for delivery to the gastrointestinal tract.

10. The method of claim 5, further comprising the step of compressing the solid formulation to form a tablet.

11. In a method for administering dehydroepiandrosterone (DHEA) to obtain an ameliorative result, the improvement comprising administering a pharmaceutically acceptable amount of DHEA, wherein at least 85% of the DHEA is present as the form I polymorph.

12. The method of claim 11, wherein at least 90% of the DHEA is present as the form I polymorph.

13. The method of claim 11, wherein at least 95% of the DHEA is present as the form I polymorph.

14. The method of claim 11, wherein at least 99% of the DHEA is present as the form I polymorph.

15. The method of claim 11, wherein said ameliorative result is treatment of systemic lupus erythematosus.

16. The method of claim 11, wherein said ameliorative result is prevention or reduction of loss of bone density.

17. The method of claim 11, wherein said ameliorative result is treatment of chronic fatigue syndrome or fibromyalgia.

18. A pharmaceutical formulation comprising dehydroepiandrosterone (DHEA), at least 85% of which is present as the form II polymorph, and at least one pharmaceutical excipient.

19. The formulation of claim 18, wherein at least 90% of said dehydroepiandrosterone (DHEA) is present as the form II polymorph.

20. The formulation of claim 18, wherein at least 95% of said dehydroepiandrosterone (DHEA) is present as the form II polymorph.

21. The formulation of claim 18, wherein at least 99% of said dehydroepiandrosterone (DHEA) is present as the form II polymorph.

22. A method for preparing a solid DHEA formulation, said method comprising:  
mixing at least one solid pharmaceutical excipient with dehydroepiandrosterone (DHEA), at least 85% of which is present as the form II polymorph.

23. The method of claim 22, wherein at least 90% of said dehydroepiandrosterone (DHEA) is present as the form II polymorph.

24. The method of claim 22, wherein at least 95% of said dehydroepiandrosterone (DHEA) is present as the form II polymorph.

25. The method of claim 22, wherein at least 99% of said dehydroepiandrosterone (DHEA) is present as the form II polymorph.

26. The method of claim 22, further comprising the step of placing the solid formulation into a capsular container suitable for delivery to the gastrointestinal tract.

27. The method of claim 22, further comprising the step of compressing the solid formulation to form a tablet.

28. In a method for administering dehydroepiandrosterone (DHEA) to obtain an ameliorative result, the improvement comprising administering a pharmaceutically acceptable amount of DHEA, wherein at least 85% of the DHEA is present as the form II polymorph.

29. The method of claim 28, wherein at least 90% of the DHEA is present as the form II polymorph.

30. The method of claim 28, wherein at least 95% of the DHEA is present as the form II polymorph.

31. The method of claim 28, wherein at least 99% of the DHEA is present as the form II polymorph.

32. The method of claim 28, wherein said ameliorative result is treatment of systemic lupus erythematosus.

33. The method of claim 28, wherein said ameliorative result is prevention or reduction of loss of bone density.

34. The method of claim 28, wherein said ameliorative result is treatment of chronic fatigue syndrome or fibromyalgia.

35. A method for controlling the bioavailability of a DHEA formulation, the method comprising: administering to a subject a DHEA formulation comprising DHEA and a pharmaceutical excipient, wherein said DHEA in said formulation consists of a preselected, known ratio of DHEA polymorphs.

Ad  
A-7